Trial Profile

Use of the NMF biomarker as predictive diagnostic for effective use of cyclosporine in the treatment of atopic dermatitis

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Dupilumab (Primary) ; Corticosteroids
Indications Atopic dermatitis
Focus Biomarker; Therapeutic Use
Acronyms NMF-CsA trial; NMF-CsA-Dupi Trial

Most Recent Events

17 Aug 2021 Status changed from not yet recruiting to recruiting.
06 May 2021 Status changed to not yet recruiting.
04 Jul 2020 Status changed from not stated to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com